UK-based company which specializes in automated analytical instrumentation that simplifies at-line protein quantification
Abselion has raised €8.0M across 1 funding round from 6 investors, most recently a Series A round in Dec 2024. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-12-09 | Series A | €8.0M |
| BGF,BioProcess 360 Partners,Existing investors,M Ventures,R42 Group,Untitled Ventures |
| View deal → |
